VAL 1000

Drug Profile

VAL 1000

Alternative Names: VAL-1000

Latest Information Update: 27 Aug 2015

Price : $50

At a glance

  • Originator Senz Oncology
  • Developer Allyence Research; Senz Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 27 Aug 2015 No recent reports on development identified - Phase-I/II for Acute lymphoblastic leukaemia, Acute myeloid leukaemia and Myelodysplastic syndromes in Australia (PO)
  • 22 Aug 2012 Clinical trials in Leukaemia in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top